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tioBackground: The accurate clinical assessment of melanocytic neoplasms is a challenge for clinicians.
Currently, obtaining a biopsy specimen and conducting a histologic examination is the standard of care.
The incidence of melanoma in white populations is high, resulting in a large number of biopsy specimens.Objective: The objective of this study is to develop a noninvasive genomic method using mRNA to classify
pigmented skin lesions as either benign or malignant.Methods: An adhesive patch method was used to obtain cells from the surface of melanocytic lesions.
mRNA was extracted and a genomic signature was formulated in a training set of benign and malignant
melanocytic neoplasms and subsequently tested in a validation set.Results: A 2-gene signature assessing the expression levels of CMIP and LINC00518 was able to
differentiate melanomas from nevi in an independent validation set of 42 melanomas and 22 nevi with a
sensitivity of 97.6% and specificity of 72.7%.Limitations: Larger and more diverse sets of melanomas and nevi are needed for additional validation of
the molecular expression profiling in various subsets of melanocytic neoplasms.Conclusion: Our data suggest that mRNA molecular signatures can serve as a highly useful noninvasive
method of differentiating melanoma from nevi and decrease the number of unnecessary biopsies. ( J Am
Acad Dermatol 2014;71:237-44.)
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qRT-PCR: quantitative real-time polymerase chain
reaction
ROC: receiver operator characteristicT
he incidence of melanoma is increasing at a
rate of 3% to 7% per year for fair-skinned
white populations, faster than any other
major cancer.1,2 While mortality from almost all
preventable cancers has markedly decreased since
1975,3,4 melanoma-related mortality remains steady,
increasing up to 6.5% in certain patient populations
annually.4 The American Cancer Society (ACS)
estimates that approximately 76,100 new cases of
melanoma will be diagnosed, resulting in 9710
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238 Gerami et alThin melanomas have an excellent prognosis. In
situ melanoma has a cure rate of virtually 100%, and
early invasive melanomas with a Breslow depth of
\1 mm have a 10-year survival rate of [90%.6,7
Conversely, tumors with a Breslow depth [4 mm
have a 10-year survival rate of\50%.6 A number of
studies have shown that early detection through aCAPSULE SUMMARY
d Developmental studies show that
molecular signatures may be an accurate
noninvasive method of identifying
melanomas.
d This study shows that our previous
mRNA signature could be reduced to 2
genes (CMIP and LINC00518) while still
accurately discriminating melanomas
and nevi.
d This method has the potential to reduce
unnecessary biopsy procedures.skin examination allows for
diagnosis at an earlier and
more curable stage of dis-
ease.8-11 In 1 study, screening
skin examinations reduced
mortality by 63%.8
Currently, obtaining a bi-
opsy specimen and con-
ducting a histologic
examination is the standard
of care for the evaluation of
clinically suspicious pig-
mented skin lesions. A mea-
sure known as number
needed to treat (NNT) is
used to measure physician
accuracy in assessing pig-
mented skin lesions. This value is determined by
dividing the total number of biopsy specimens
obtained to exclude melanoma by the total number
of melanomas according to histopathologic assess-
ment. Various studies analyzing this value have
reported NNT values between 8 for experienced
dermoscopy users and [30 for other health care
professionals.12-14 To diagnose the 76,690 invasive
melanomas and 60,000 in situ melanomas predicted
by the ACS using a conservative NNT between 8 to 15
would require 1 to 2 million skin biopsy specimens.2
Histopathology, the criterion standard for the
diagnosis of melanocytic neoplasms, has limita-
tions.15-18 The histopathologic examination consists
of a 2-dimensional morphologic assessment from a
single moment in time of 3-methick sections of
tumors that are often[4 mm. Investigators perform-
ing dermoscopic evaluations of melanocytic neo-
plasms have noted that some lesions that are likely
early melanomas based on their clinical behavior
may not meet the full histologic criteria for mela-
noma.19 In addition, the discrepancy between the
increased incidence of melanoma and death from
melanoma has led many investigators to speculate
that a subset of indolent melanomasmay exist. These
tumors may meet the histologic criteria for mela-
noma but have an indolent clinical behavior.20
In this study, we evaluated an alternative method
of assessing melanocytic neoplasms using mRNA
obtained from the surface of lesions using a nonin-
vasive adhesive patch technology. Our data suggestthat mRNA signatures can improve physicians’ NNT
value and the overall quality of patient care.
METHODS
Between 2004 and 2010, DermTech International
(DTI) created a prospectively ascertained bio-
repository of both normal and diseased skinspecimens obtained by
noninvasive adhesive patch
sampling, with subsequent
surgical biopsy and dermato-
pathologic evaluation. The
biorepository contained
[4700 adhesive patche
sampled specimens. All study
protocols were reviewed and
approved by a central institu-
tional review board (ie, the
Western Institutional Review
Board) along with the institu-
tional review boards at the
sites that submitted speci-
mens (a full site list is pro-
vided at the end of thisarticle). The study was conducted according to the
principles of the Declaration of the Helsinki, and all
subjects provided informed consent.
Inclusion criteria
Subjects were eligible if they were at least 18 years
of age and had a clinically suspicious pigmented
lesion that was $ 4 mm in diameter. If the patient
hadmultiple clinically suspicious lesions, they had to
be at least 4 mm apart.
Exclusion criteria
Subjects were excluded if they had used topical
medications or systemic steroids within 30 days of
beginning the study; if the subject had a generalized
skin disorder not related to skin cancer; if the
pigmented lesion was in the acral or vulvar region;
if the subject was allergic to the adhesive patch or
latex rubber; if in the past 30 days they had
participated in an investigational study; or if the
patient had clinical findings suggestive of an
advanced stage lesion.
Adhesive patch procedure
Pigmented lesions were sampled by adhesive
patch before biopsy specimens were obtained. The
patch was applied to the site and briskly rubbed at
least 15 times in a circular motion with a 1-cm
diameter rounded device or plastic tube before the
patch was removed. The border of the lesion was
demarcated on the patch. A total of 4 patches were
Table I. Discovery cohort, set A
Invasive
melanoma
Melanoma
in situ Nevi
Other
(ie, NMSC,
seborrheic
keratosis,
and lentigo)
Site
Trunk 20 10 46 7
Extremity 12 7 3 7
Head and
neck
13 7 3 5
Age (y)
Range 23-87 36-92 20-73 20-91
Mean 55.9 65.3 43.2 63.0
Sex
Male 29 17 28 12
Female 15 7 24 7
Total 45* 24 52 19
NMSC, Nonmelanoma skin cancer.
*The sex of 1 patient with invasive melanoma was not indicated.
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stored at 208C or below within 10 minutes of
stripping. The patches were shipped to DTI on dry
ice, by express mail, for RNA extraction within 1
week.
Biopsy
After the adhesive patch procedure, the lesion
was excised according to standard clinical practice.
All tissues removed were formalin fixed and
embedded in paraffin and sectioned for histopatho-
logic analysis. The slides were sent to a central
dermatopathologist. Three separate dermatopathol-
ogists (the site pathologist and 2 central pathologists
contracted by DTI) were involved in the reading of
each case. Inclusion criteria required agreement
among all 3 dermatopathologists. All were blinded
to the molecular results.
Quantitation of gene expression
All laboratory personnel were blinded to the
pathology diagnoses. The outlined lesional portion of
each patch was manually dissected, and the 4 patches
for each lesion were pooled for additional processing.
Total RNAwas isolated for each pigmented lesion and
used for cDNAsynthesis; cDNAwas subsequentlyused
for preamplification and quantitative real-time poly-
merase chain reaction (qRT-PCR) studies using
standard Taqman chemistry. RNA was isolated using
Ambion MELT (Life Technologies, Foster City, CA),
cDNA synthesis was performed using SuperScript
VILO (Life Technologies), and preamplification was
performed using a custom pool of primers and probes
for all genes assayed (Life Technologies). Quantitation
of gene expression levels was performed using the
QuantStudio OpenArray system (Life Technologies).
Expression levels of candidate signature genes for each
specimen were normalized to the geometric mean of
expression levels of 3 housekeeping genes (eg, ACTB
[beta-actin], B2M [beta-2-microglobulin], and PPIA
[peptidylprolyl isomerase A]) for that specimen.
Statistical analysis
An optimal classification signature was created
separately for each of 2 independently ascertained
datasets. The selection of genes for inclusion in the
classification signature was performed using sto-
chastic gradient boosting analysis coupled with
bootstrap logistic decision tree modeling (TreeNet;
Salford Systems, San Diego, CA) and logistic regres-
sion (R; R Foundation for Statistical Computing)21 on
a previously determined gene list.22,23 TreeNet was
used to create the classification algorithm and to
determine each gene’s relative importance. A
TreeNet battery incorporating 10 independentlyderived models was constructed using random
resampling and replacement from 140 specimens to
select sets of 91 for training and 49 for testing in each
model, with each set comprised of approximately
50% melanoma and 50% nevi. Dichotomous disease
status was the dependent variable, and the gene
expression values were independent variables.
Logistic regression was similarly used to assess the
performance of each possible gene pair taken from
the previously determined gene list. All specimens
used had complete data for gene expression values.
The classification algorithm computes a score be-
tween 0 and 1 for each specimen based on the
measured gene expression inputs. Sensitivity, spec-
ificity, negative predictive value (NPV), positive
predictive value (PPV), receiver operator character-
istic (ROC) curves, and area under the ROC curve
(AUC) were calculated using R software.RESULTS
Gene expression classification of melanoma
A previously discovered, high accuracy 15-gene
classification signature was used as a starting point
for validation.23 The relative importance of each
gene within the total profile was assessed. Most of
the 15 genes did not make large contributions, with a
relative importance of # 30%. This served as an
impetus to investigate reducing the number of genes
in the signature.
All 105 pairwise combinations from within the
previous 15-gene signature were investigated for
accuracy by bootstrap multivariate logistic regres-
sion using a previous 140-specimen set (Table I,
set A) including 69 melanomas, 52 nevi, and 19 other
Fig 1. Performance of gene pairs from the 15-gene
classifier. Histogram of all 105 pairwise combinations
from the 15 genes of the previously reported melanoma
signature, binned by the area under the curve of the
receiver operating characteristic (AUC-ROC) for each pair.
The width on the x axis of each column represents the
lower and upper limits of the AUC-ROC for that bin. The
number of genes in each bin is represented by the height
of the column on the y axis.
Table II. Validation cohort, set B
Invasive
melanoma
Melanoma
in situ Nevi
Other
(ie, NMSC,
seborrheic
keratosis,
and lentigo)
Site
Trunk 13 2 16 1
Extremity 12 5 3 —
Head and
neck
3 7 2 —
Age (y)
Range 20-83 40-83 18-82 35
Mean 54.19 63.14 41.14 35
Sex
Male 16 11 15 0
Female 12 3 6 1
Total 28 14 21 1
NMSC, Nonmelanoma skin cancer.
Table III. Pathology diagnosis versus expression
signature classification, classifier A on set B
Gene expression
classification
Pathology diagnosis
Melanoma Nevi
Melanoma 41 6
Nonmelanoma 1 16
Sensitivity 41/42 (97.6%) —
Specificity — 16/22 (72.7%)
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was created by randomly sampling the biorepository
log using a balanced design of 100 melanoma and
100 nonmelanoma subjects. Case attrition from
insufficient quantity of stored material, specimen
signals below the limit of detection, exclusion
because of use in earlier studies, or major discor-
dance among the 3 expert dermatopathologists
resulted in a set of 140 specimens (Table I, set A).
As shown in Fig 1, the mean AUC of each gene pair’s
iterations ranged from a low of 0.72 to a high of 0.94
(an AUC of 1.00 is a perfect classification system).
Additional analysis of the AUC for larger combina-
tions of the genes revealed that optimal classification
is given by 2 genes; the inclusion of additional genes
did not improve accuracy. The gene pairs with
average AUCs above 0.90 were further investigated
using TreeNet analysis (Fig 1).
CMIP and LINC00518 was the best performing
pair in both logistic regression and TreeNet. The
signature using those 2 genes was then validated in a
newly tested set of 64 cases consisting of 42
melanomas and 22 nevi (Table II, set B). This set
was created in the same fashion as set A and resulted
in 64 specimens (Table II, set B). Table III gives the 2
3 2 table of disease status versus expression signa-
ture classification; Fig 2 shows a graphic distribution
of the cases’ scores. The resulting sensitivity was97.6% and specificity was 72.7%. The NPV was 94%
at the study prevalence of 67% melanoma, and was
99.6% at an adjusted melanoma prevalence of 10% to
more closely reflect what is reported for general
dermatology practices (the ratio of nevi to melanoma
was numerically adjusted to 9:1 while maintaining
the sensitivity and specificity values).
A cross-validation was subsequently performed
by similarly using the same 2 genes to create a
classification algorithm from set B and applying it
to the independent set A. Comparable validation
accuracies were seen, with sensitivity of 97% and
specificity of 68%. Table IV gives the 2 3 2 table of
disease status versus expression signature classifica-
tion; Fig 3 shows a graphic distribution of the cases’
scores. The NPV was 88% at the study prevalence of
73% melanoma, and was 99.4% at an adjusted
melanoma prevalence of 10% to more closely reflect
what is reported for general dermatology practices
(Table III).Limitations
A significant proportion of cases were lost
because of insufficient mRNA or mRNA signal below
Fig 2. Case distribution of classifier scores, set B. Distribution of independent set B cases
scored by the set A classifier. The x axis represents the case number. The y axis represents the
algorithmic score based on expression levels of a 2-gene classifier. Nevi are plotted on the left as
black circles; melanomas are plotted on the right as black triangles.
Table IV. Pathology diagnosis versus expression
signature classification, classifier B on set A
Gene expression
classification
Pathology diagnosis
Melanoma Nevi
Melanoma 67 23
Nonmelanoma 2 48
Sensitivity 67/69 (97.1%) —
Specificity — 48/71 (67.6%)
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studies. The loss of cases related to mRNA insuffi-
ciency could limit clinical use and/or require
repeated sampling attempts in order to obtain an
adequate specimen; process improvements are un-
derway that will address this important issue. It is not
clear what bias that may have introduced. The 1 case
in set B diagnosed as melanoma by histopathology
but not by the gene classifier was a lentigo maligna
melanoma in situ. It would be worthwhile in future
studies using larger datasets to determine if there is a
different level of accuracy when assessing the
various subtypes of melanoma—including mela-
nomas from acral or vulvar skin, which were not
included in this study. Cases were also limited to a
minimum diameter of 4 mm.
CONCLUSIONS
A previous report25 has described gene expres-
sion signatures that accurately discriminated mela-
nomas from nevi and other nonmelanoma
specimens. These gene sets were derived from theresults of an initial genome-wide microarray exper-
iment and further refined to a 15-gene set by
computational analyses. We now report that 2 genes,
CMIP and LINC00518, have an equivalent classifica-
tion ability. The 2 genes’ combined ability to
accurately discriminate between melanoma and
nonmelanoma cases represents a novel biomarker
discovery arrived at via top-down genomic data
mining. This approach was agnostic to existing
biologic knowledge of disease states and processes,
and did not involve the biases of a priori knowledge.
Therefore, any assessment of the roles of CMIP and
LINC00518 in the pathophysiology of melanoma
must be constructed from our current understanding
of those genes’ functions.
The CMIP gene is involved in oncogenesis via the
modulation of key signaling pathways. CMIP can
promote apoptosis by downregulating nuclear factor
kappa B (NF-kB),25,26 a transcription factor that
responds to abnormal cellular stimuli and is a key
component in cell proliferation, survival, and inflam-
matory and immune responses. In this study, CMIP
mRNA was downregulated in melanoma relative to
nonmelanoma lesions; the CMIP reduction may
decrease its inhibitory effect on NF-kB, leading to
decreased control of proliferation with subsequent
melanomagenesis. NF-kB is dysregulated in many
tumors.27
LINC00518 mRNA was upregulated in melanoma
relative to nonmelanoma lesions. Its chromosomal
location is 6p24.3, immediately adjacent to the 6p25
region which has frequent copy number gains in
melanoma.28 It is a member of the large class of
Fig 3. Case distribution of classifier scores, set A. Distribution of independent set A cases
scored by the set B classifier. The x axis represents the case number. The y axis represents the
algorithmic score based on expression levels of a 2-gene classifier. Nevi are plotted on the left as
black circles; melanomas are plotted on the right as black triangles.
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RNAs (lncRNAs), which do not code for proteins.
Recent studies on melanoma tissue specimens and
cell lines have shown the importance of lncRNAs as
regulatory molecules influencing proliferation, dif-
ferentiation, and cellular processes. A number of
lncRNAs are differentially expressed in melanoma
cell lines versus melanocytes and keratinocytes in
culture.29 One study of primary melanomas and
lymph node metastases identified a lncRNA gene
that may promote metastatic potential when highly
expressed in primary tumors.30 The authors postu-
lated that the overexpression of certain lncRNAs
plays a role in the development of human mela-
noma. A recent study of uveal melanomas revealed
alternative splicing of protein coding genes associ-
ated with upregulation of a lncRNA, and indicated
that a possible function of lncRNA is to rearrange and
control protein coding regions of the human
genome.31
In vivo, mRNA produced by melanocytes is car-
ried in organelles and/or vesicles that are phagocy-
tized by epithelial cells.32 The adhesive patch
method is noninvasive, only removing a superficial
layer of epithelial cells, and does not result in any
wound or require any down time from physical
activity or work. While the overall morbidity associ-
ated with obtaining a skin biopsy specimen is quite
low, each specimen obtained may result in
decreased physical activity, time off from work,
anxiety, and scarring. In patients with dysplastic
nevus syndrome, this procedure would allow for the
simultaneous evaluation of a greater number ofatypical nevi, whereas obtaining more than 3 or 4
excisional biopsies at one time could result in
considerable discomfort and significant wound care.
Currently, the NNT for pigmented lesions is
between 10 and 30; a single patient diagnosed with
2 melanomas in their lifetime may require 20 to 60
biopsy specimens to diagnose melanoma. In addi-
tion, obtaining biopsy specimens from some pig-
mented lesions on the face, genitalia, or other
sensitive anatomic locations may result in unsightly
scars. The high sensitivity (97.6%) of the assay
accompanied with a specificity of 72.7% could
significantly decrease the number of unnecessary
biopsy specimens, resulting in a significant improve-
ment in quality of life.
Six of 22 cases with a histologic diagnosis of nevus
had a molecular score consistent with a diagnosis of
melanoma. Interestingly, among those 6 cases, 3 had
a histologic reading of dysplastic nevus with severe
atypia. Unfortunately, it is impossible to determine
whether these 3 cases were truly false positives or
actually early melanomas.
In summary, this procedure represents a novel
noninvasive molecular approach to evaluating mel-
anocytic neoplasms when coupled with expression
analysis of the genes described in this report.
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